Role of paliperidone extended-release in treatment of schizoaffective disorder

Código QR

Role of paliperidone extended-release in treatment of schizoaffective disorder

Carla M Canuso1, Ibrahim Turkoz2, Dong Jing Fu3, Cynthia A Bossie31External Innovation Neuroscience Therapeutic Area, 2Biostatistics, Johnson &amp; Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA; 3CNS Medical Affairs, Ortho-McNeil Janssen Scientific Affairs, LLC, T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carla M Canuso, Ibrahim Turkoz, Dong Jing Fu, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/adcc3cc9eec44cc5bcc3b18f4f62850a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Ibrahim Turkoz, et al.
Publicado: (2008)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino J, et al.
Publicado: (2012)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa R, et al.
Publicado: (2015)

Role of extended release quetiapine in the management of bipolar disorders
por: Rayan K Al Jurdi, et al.
Publicado: (2010)

Combination therapy or monotherapy for the depressed type of schizoaffective disorder
por: Lubomira Iz&aacute;kov&aacute;, et al.
Publicado: (2009)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
por: Si TM, et al.
Publicado: (2015)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai SL, et al.
Publicado: (2015)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas A, et al.
Publicado: (2017)

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients
por: Charnsil C, et al.
Publicado: (2013)

Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature
por: Daniel J Abrams, et al.
Publicado: (2008)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa JK, et al.
Publicado: (2012)

Management of obsessive-compulsive disorder with fluvoxamine extended release
por: L&iacute;dia Ordacgi, et al.
Publicado: (2009)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa T, et al.
Publicado: (2011)

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili N
Publicado: (2012)

Interaction between paliperidone extended release and TS-1&reg;, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
por: Yasui-Furukori N, et al.
Publicado: (2013)

Patients with schizophrenia or schizoaffective disorder who receive multiple electroconvulsive therapy sessions: characteristics, indications, and results
por: Iancu I, et al.
Publicado: (2015)

Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review
por: Steven C Stoner, et al.
Publicado: (2007)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga J, et al.
Publicado: (2015)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang FD, et al.
Publicado: (2017)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
por: Shi C, et al.
Publicado: (2016)

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
por: Endicott J, et al.
Publicado: (2012)

The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens J
Publicado: (2011)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Delia Bishara
Publicado: (2010)

Paliperidone ER: a review of the clinical trial data
por: Philip G Janicak, et al.
Publicado: (2007)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
por: Srihari Gopal, et al.
Publicado: (2011)

Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
por: Barbara Błaszczyk, et al.
Publicado: (2010)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes KC
Publicado: (2011)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
por: Li HF, et al.
Publicado: (2015)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash AI, et al.
Publicado: (2019)

Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
por: Jan K Buitelaar, et al.
Publicado: (2009)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang H, et al.
Publicado: (2016)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara M, et al.
Publicado: (2013)

The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode
por: Findling RL, et al.
Publicado: (2014)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang F, et al.
Publicado: (2015)

Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder
por: Tian-Xiang Zhang, et al.
Publicado: (2021)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
por: Chen CY, et al.
Publicado: (2018)

Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures
por: Carol M Ulloa, et al.
Publicado: (2009)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
por: Samtani MN, et al.
Publicado: (2013)

The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia
por: Chiou CF, et al.
Publicado: (2015)